Pasar al contenido principal

EXPLOTANDO LA SENESCENCIA CELULAR PARA LA TERAPIA DEL CANCER

PID2021-125479OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PUBLICA GALEGA INSTITUTO DE INVESTIGACIÓN SANITARIA DE SANTIAGO DE COMPOSTELA (FIDIS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Guidelines for minimal information on cellular senescence experimentation in vivo

  • Ogrodnik, Mikolaj
  • Carlos Acosta, Juan
  • Adams, Peter D.
  • D'Adda di Fagagna, Fabrizio
  • Baker, Darren J.
  • Bishop, Cleo L.
  • Chandra, Tamir
  • Collado, Manuel
  • Gil, Jesús
  • Gorgoulis, Vassilis
  • Gruber, Florian
  • Hara, Eiji
  • Jansen-Dürr, Pidder
  • Jurk, Diana
  • Khosla, Sundeep
  • Kirkland, James L.
  • Krizhanovsky, Valery
  • Minamino, Tohru
  • Niedernhofer, Laura J.
  • Passos, João F.
  • Ring, Nadja A. R.
  • Redl, Heinz
  • Robbins, Paul D.
  • Rodier, Francis
  • Scharffetter-Kochanek, Karin
  • Sedivy, John M.
  • Sikora, Ewa
  • Witwer, Kenneth
  • Von Zglinicki, Thomas
  • Yun, Maximina H.
  • Grillari, Johannes
  • Demaria, Marco
Cellular senescence is a cell fate triggered in response to stress and is characterized by stable cell-cycle arrest and a hypersecretory state. It has diverse biological roles, ranging from tissue repair to chronic disease. The development of new tools to study senescence in vivo has paved the way for uncovering its physiological and pathological roles and testing senescent cells as a therapeutic target. However, the lack of specific and broadly applicable markers makes it difficult to identify and characterize senescent cells in tissues and living organisms. To address this, we provide practical guidelines called "minimum information for cellular senescence experimentation in vivo" (MICSE). It presents an overview of senescence markers in rodent tissues, transgenic models, non-mammalian systems, human tissues, and tumors and their use in the identification and specification of senescent cells. These guidelines provide a uniform, state-of-the-art, and accessible toolset to improve our understanding of cellular senescence in vivo., Work in the laboratory of M.C. is funded by grant PID2021-125479OB-I00 from MCINN/AEI/FEDER, UE. J. Grillari kindly acknowledges support by the Austrian Science Fund (Der O ̈ sterreichischer Wissenschaftsfonds; FWF) and ‘Herzfelder’sche Familienstif- tung project P35268-B. F.d.d.F’s laboratory is supported by ERC advanced grant (TELORN AGING—835103); AIRC-IG (21762); Telethon (GGP17111); AIRC 5X1000 (21091); Progetti di Ricerca di Interesse Nazionale (PRIN) 2015 ‘‘ATR and ATM-mediated control of chromosome integrity and cell plasticity’’; Progetti di Ricerca di Interesse Nazionale (PRIN) 2017 ‘‘RNA and genome Instability’’; Progetto AriSLA 2021 ‘‘DDR & ALS’’; POR FESR 2014-2020 Regione Lombar- dia (InterSLA project); FRRB—Fondazione Regionale per la Ricerca Bio- medica—under the frame of EJP RD, the European Joint Programme on Rare Diseases with funding from the European Union’s Horizon 2020 research and innovation program under the EJP RD COFUND-EJP NO 825575; co- funding European Union – Next Generation EU, in the context of The National Recovery and Resilience Plan, Investment Partenariato Esteso PE8 ‘‘Conseguenze e sfide dell’invecchiamento,’’ Project Age-It (Ageing Well in an Ageing Society), and National Center for Gene Therapy and Drugs based on RNA Technology, CN00000041. C.L.B. is funded by the Biotechnology and Biological Sciences Research Council (BBSRC, grant BB/X006972/1) L.J.N. and P.D.R. are supported by P01 AG043376, U19 AG056278, RO1 AG063543, P01 AG062413, U54 AG079754, and U54 AG076041 from the Na- tional Institutes of Health and an Aligning Science Across Parkinson’s grant ASAP-000592 from the Michael J. Fox Foundation. F.R is supported by grants from the Canadian Institute for Health Research (PJT173341), the Natural Sciences and Engineering Research Council (NSERC – RGPIN-2022-04385) by a FRQS junior I-II-senior career awards (22624, 33070, and 281706), and the Cancer Research Society (CRS) in part- nership with Ovarian Cancer Canada (20087). T.v.Z. is supported by BBSRC grant no. BB/S006710/1 and H2020 WIDE- SPREAD Project 857524. D.J.B. is supported by grants from the National Institutes of Health (R01AG053229, R01AG068076, and U54AG079779) and the Glenn Founda- tion for Medical Research. E.S. was supported by the National Science Center, grant UMO-2019/35/B/ NZ4/01920. F.G. gratefully acknowledge the financial support of the Federal Ministry for Labour and Economy of Austria and the National Foundation for Research, Technology, and Development of Austria to the Christian Doppler Laboratory for Skin Multimodal Imaging of Aging and Senescence. Work in the Jansen-Du ̈ rr lab was supported by the Austrian Science Funds (FWF Project FG 2400 B, SENIOPROM) and the European Union (MSCA Proj- ect COFUND-ARDRE). J.F.P. would like to acknowledge funding from the NIH grants R01AG068048, R01AG82708, UG3CA268103, and The Glenn Foundation For Medical Research. D.J. would like to acknowledge funding from NIH grant R01 AG068182 and Hevolution/AFAR. M.H.Y. is supported by DFG (22137416, 450807335, and 497658823) grants and TUD & CRTD funds. J.L.K. is supported by NIH grants R37AG013925 and R33AG061456; The Connor Fund, Robert J. and Theresa W. Ryan, and the Noaber Foundation. V.G. is supported by the National Public Investment Program of the Ministry of Development and Investment/General Secretariat for Research and Technology, in the framework of the Flagship Initiative to address SARS-CoV-2 (2020SE01300001); the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH–CREATE–INNOVATE (project codes: T2EDK-02939 and T2EDK-03266); Sonia Kotopoulos donation; P. Galanis and Co. donation (lab supplies); and NKUA-SARG grant 70/3/8916. V.K. is supported by European Research Council grant 856487, Israel Sci- ence Foundation grants 2633/17 and 1626/20, and DFG-CRC 1506 ‘‘Aging at Interfaces.’’ M.D. is funded by the Dutch Research Council (NWO) Talent Program (VIDI 09150172010029), Dutch Organization for Health Research and Development (ZonMw), Dutch Cancer Foundation (KWF), Health Holland, American Federa- tion for Aging Research (AFAR), and Hevolution Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inhibition of lung tumorigenesis by transient reprogramming in cancer cells

  • Pedrosa, Pablo
  • Zhang, Zhenguang
  • Nuñez-Quintela, Victor
  • Macias, David
  • Ge, Jianfeng
  • Denholm, Mary
  • Dyas, Anna
  • Estevez-Souto, Valentin
  • Lado-Fernandez, Patricia
  • Gonzalez, Patricia
  • Gomez, Maria
  • Martin, Jose Ezequiel
  • Da Silva-Alvarez, Sabela
  • Collado, Manuel
  • Muñoz-Espín, Daniel
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41419-024-07207-2., Oncogenic transformation and Oct4, Sox2, Klf4 and c-Myc (OSKM)-mediated induction of pluripotency are two independent and incompatible cellular fates. While continuous expression of OSKM can convert normal somatic cells into teratogenic pluripotent cells, it remains speculative what is the impact of transient OSKM expression in cancer cells. Here, we find that OSKM expression limits the growth of transformed lung cells by inducing apoptosis and senescence. We identify Oct4 and Klf4 as the main individual reprogramming factors responsible for this effect. Mechanistically, the induction of cell cycle inhibitor p21 downstream of the reprogramming factors acts as mediator of cell death and senescence. Using a variety of in vivo systems, including allografts, orthotopic transplantation and KRAS-driven lung cancer mouse models, we demonstrate that transient reprogramming by OSKM expression in cancer cells impairs tumor growth and reduces tumor burden. Altogether, our results show that the induction of transient reprogramming in cancer cells is antitumorigenic opening novel potential therapeutic avenues in oncology., P.P., V.N.Q. and P.L-F. were supported by predoctoral fellowships from GAIN (IN606A-2017/002, IN606A-2021/016 and ED481A-2020/066, respectively), from Xunta de Galicia. S.D.S.-A. was supported by a postdoctoral fellowship from GAIN (IN606B-2021/011), Xunta de Galicia. Work in the laboratory of M.C. is funded by grants from MCINN/AEI/FEDER, UE (PID2021-125479OB-I00) and GAIN, Xunta de Galicia (IN607D2021/08). DM-E’s laboratory was supported by the CRUK Cambridge Centre Early Detection Program (RG86786), by a CRUK Program Foundation Award (C62187/A29760), by a CRUK Early Detection OHSU Project Award (C62187/A26989), an MRC New Investigator Research Grant (NIRG) (MR/R000530/1), and a Darley/Sands Downing College Fellowship (G109261)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Transcriptional repression of SOX2 by p53 in cancer cells regulates cell identity and migration

  • Lado-Fernández, Patricia
  • Vilas, Jéssica M
  • Fernandes, Tânia
  • Carneiro, Carmen
  • Da Silva-Álvarez, Sabela
  • Estévez-Souto, Valentín
  • Pedrosa, Pablo
  • González-Barcia, Miguel
  • Abatti, Luis E
  • Mitchell, Jennifer A
  • Rivas, Carmen
  • Moreno-Bueno, Gema
  • Vidal, Anxo
  • Collado, Manuel
During cancer development and progression, many genetic alterations lead to the acquisition of novel features that confer selective advantage to cancer cells and that resemble developmental programs. SRY-box transcription factor 2 (SOX2) is one of the key pluripotency transcription factors, expressed during embryonic development and active in adult stem cells. In cancer, SOX2 is frequently dysregulated and associated with tumor stemness and poor patient survival. SOX2 expression is suppressed in differentiated cells by tumor suppressor proteins that form a transcriptional repressive complex. We previously identified some of these proteins and found that their absence combined with deficiency in Trp53 leads to maximal dysregulated expression of Sox2. Using cancer cell lines of different origin and with different p53 status, we show here that manipulating TP53 to restore or decrease its activity results in repression or induction of SOX2, respectively. Mechanistically, we observed that the regulation of SOX2 expression by TP53 is transcriptional and identified Trp53 bound to the promoter region and the Sox2 Regulatory Region 2 enhancer of Sox2. Forcing high levels of SOX2 in cancer cells leads to morphological changes that molecularly correspond to the acquisition of a more mesenchymal phenotype, correlating with an increased migratory capacity. Finally, the analysis of human breast cancer samples shows that this correlation between TP53 status, levels of expression of SOX2, and a more metastatic phenotype is also observed in cancer patients. Our results support the notion that lack of TP53 in tumor cells results in deregulated expression of developmental gene SOX2 with phenotypic consequences related to increased malignization., Work in the laboratory of Manuel Collado is funded by grants from MCINN/AEI/FEDER, UE (PID2021-125479OB-I00) and GAIN, Xunta de Galicia (IN607D2021/08 and IN607B2024/13). The laboratory of Anxo Vidal is funded by MCINN/AEI/FEDER, UE (PLEC2022-009476), and Xunta de Galicia (ED431C 2023/10). Patricia Lado-Fernández was supported by a predoctoral fellowship from GAIN, Xunta de Galicia (ED481A-2020/066) and funds from Deputación da Coruña (BINV-CS/2023 #2023000020568); Jéssica M. Vilas and Pablo Pedrosa were supported by predoctoral fellowships from GAIN, Xunta de Galicia (PRE/2012/317 and IN606A-2017/002, respectively); Sabela Da Silva-Álvarez was supported by a postdoctoral fellowship from GAIN (IN606B-2021/011), Xunta de Galicia, and Juan de la Cierva contract Grant (JDC2022-049032-I) funded by MICIU/AEI/10.13039/501100011033 and by European Union NextGenerationEU/PRTR., Peer reviewed